港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

高瓴概念

480.455

+7.0971.50%

漲家數：43

跌家數：8

平家數：4

市盈率：- -

高：483.192

開：472.413

低：468.212

收：473.358

資料載入中...

港股異動 | 藥明康德(02359)再漲超5% 一季度淨利增超89% 高盛稱公司有空間在下半年提高指引

開拓藥業-B早盤漲近6% 脱髮治療臨牀試驗達主要終點

三生製藥(01530)上漲6.35%，報12.72元/股

恒生生物科技指數盤中漲超1%，藥明康德漲超5%，藥明生物、京東健康、信達生物紛紛走強。

錦欣生殖(01951)出現大手買入84.25萬股，成交價$2.9，涉資244.325萬

阿斯达克财经

港股異動 | 榮昌生物(09995)再漲超8% 一季度收入同比增近六成泰它西普gMG數據超出預期

藥明康德漲4.82% 第一季淨利同比增長89.06% 機構料TIDES業務在今年增長65%

藥明康德盤中異動股價大漲3.08%報62.000港元

榮昌生物盤中異動早盤股價大漲5.26%

三生製藥盤中異動早盤快速上漲5.02%

晶泰控股盤中異動早盤快速跳水5.04%報4.900港元

港股醫藥股走勢疲軟，百濟神州跌近6%

每日经济新闻

泰格醫藥盤中異動股價大跌5.05%

建業新生活(09983.HK)首席執行官變更

阿斯达克财经

美團－Ｗ(03690)出現大手賣出75.18萬股，成交價$129.6，涉資9.743千萬

阿斯达克财经

鐵打的高毛利流水的“醫美茅”：膠原蛋白捧出山西女首富玻尿酸富豪們身家大跌

翰森製藥(03692.HK)治療卵巢癌藥物獲國家藥監局納入突破性治療藥物

阿斯达克财经

開拓藥業(09939.HK)治療雄激素性脫髮藥物臨牀試驗達主要研究終點

阿斯达克财经

VESYNC：預期5月7日撤銷股份上市地位

VESYNC(02148.HK)私有化獲大法院批准本月7日起撤銷上市地位

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1583/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"高瓴概念","latestPrice":480.45514,"timestamp":1746173303402,"preClose":473.35806,"halted":0,"volume":268759389,"delay":0,"changeRate":0.014993,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":7.097076,"latestTime":"05-02 16:00:00","open":472.4127,"high":483.19214,"low":468.21243,"amount":6571958060.5,"amplitude":0.031646,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"pbRate":2.271165,"peRate":22.021555,"turnoverRate":0.001901,"increases":42,"decrements":11,"flats":1,"marketCap":2714015785664,"floatMarketCap":2126069050304},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":483.19214,"amplitude":0.031646,"preClose":473.35806,"low":468.21243,"pbRate":"2.271165","latestPrice":480.45514,"volume":268759389,"delay":0,"open":472.4127,"prevYearClose":446.93042,"prevWeekClose":466.075,"prevMonthClose":473.358,"prevQuarterClose":505.776,"fiveDayClose":467.752,"twentyDayClose":505.776,"sixtyDayClose":437.729,"secType":"PLATE","market":"HK","turnoverRate":0.001901,"peRate":22.021555,"marketCap":2714015785664,"floatMarketCap":2126069050304,"timestamp":1746173303402,"nameCN":"高瓴概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":43,"down":8,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532857670","title":"港股異動 | 藥明康德(02359)再漲超5% 一季度淨利增超89% 高盛稱公司有空間在下半年提高指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2532857670","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532857670?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 10:52","pubTimestamp":1746154342,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药明康德再涨超5%，截至发稿，涨5.07%，报63.2港元，成交额6004.61万港元。消息面上，药明康德公布2025年第一季度业绩，营业收入约96.55亿元，同比增长20.96%；归属于上市公司股东的净利润约36.72亿元，同比增长89.06%。高盛发表研究报告指，药明康德今年首季财报强劲，管理层维持其2025财年指引，符合该行预期，认为如果未来1至2个季度持续强势，公司有空间在下半年提高指引。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2242644610.SGD","603259","IE00BFXG1179.USD","BK1576","IE0034235188.USD","LU2471134952.CNY","02359","LU2471134523.USD","LU2471134796.USD","LU1868836914.USD","BK0216","IE00B19Z3B42.SGD","LU0106831901.USD","BK1141","IE0004086264.USD","IE0002270589.USD","LU1997244956.HKD","BK4127","LU0708995583.HKD","LU0251142724.SGD","LU1791807156.HKD","IE00B19Z3581.USD","BK4533","BK4550","LU0061475181.USD","LU1868837136.USD","BK1583","LU1997245177.USD","LU2488822045.USD","LU2237443895.HKD","BK4516","LU2237443382.USD","LU1868837300.USD","LU1046422090.SGD","LU2750360997.AUD","LU1868836591.USD","LU2237438978.USD","IE00BSNM7G36.USD","LU0742534661.SGD","LU2237443465.HKD","LU2495084118.USD","LU1868836757.USD","LU2237443549.SGD","LU2471134879.HKD","LU2045819591.USD","LU2237443978.SGD","BK4585","LU0052750758.USD","LU2750360641.GBP","LU0096364046.USD"],"gpt_icon":0},{"id":"2532644548","title":"開拓藥業-B早盤漲近6% 脱髮治療臨牀試驗達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2532644548","media":"DoNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532644548?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 10:48","pubTimestamp":1746154082,"startTime":"0","endTime":"0","summary":"5月2日，开拓药业-B（09939）早盘股价上涨5.83%，报1.27港元。公司公告显示，其KX-826与米诺地尔联合治疗男性雄激素性脱发的Ib/III期临床试验已达到主要研究终点。该试验旨在评估疗法的有效性和安全性，并为III期试验优化方案设计。基于研究成果，公司对联合疗法潜力充满信心，计划有序推进后续试验。免责声明：本文内容由开放的智能模型自动生成，仅供参考。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502105043974d0564&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502105043974d0564&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1141","BK1576","BK1574","BK1515","03347","BK1161","09939"],"gpt_icon":0},{"id":"2532985713","title":"三生製藥(01530)上漲6.35%，報12.72元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2532985713","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532985713?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 10:48","pubTimestamp":1746154081,"startTime":"0","endTime":"0","summary":"5月2日，三生制药(01530)盘中上涨6.35%，截至10:48，报12.72元/股，成交7843.07万元。三生制药是一家主要致力于开发、生产和销售医药产品，产品包括重组人血小板生成素、肿瘤坏死因子α抑制剂以及重组人促红素等，销售市场涵盖国内以及斯里兰卡、多米尼加共和国和泰国等海外市场。此外，公司通过其子公司集思有限公司,香港三生医疗有限公司和沈阳三生制药有限责任公司也从事项目管理和咨询业务。截至2024年年报，三生制药营业总收入91.08亿元、净利润20.9亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/02104850091660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1593","BK1583","BK1161","01530"],"gpt_icon":0},{"id":"2532857460","title":"恒生生物科技指數盤中漲超1%，藥明康德漲超5%，藥明生物、京東健康、信達生物紛紛走強。","url":"https://stock-news.laohu8.com/highlight/detail?id=2532857460","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532857460?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 10:47","pubTimestamp":1746154049,"startTime":"0","endTime":"0","summary":"恒生生物科技指数盘中涨超1%，药明康德涨超5%，药明生物、京东健康、信达生物纷纷走强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/02104750091629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1794554557.SGD","LU0516423091.SGD","LU1997245177.USD","LU0516423174.USD","SG9999002562.SGD","02359","LU0819121731.USD","LU0327786744.USD","LU0348735423.USD","LU0856984785.SGD","LU0348825331.USD","LU0052750758.USD","BK1610","LU2488822045.USD","LU2495084118.USD","02269","LU0307460666.USD","LU2125910500.SGD","LU0359201612.USD","LU0417516738.SGD","LU1880383366.USD","86618","LU0516422440.USD","BK1615","LU0979878070.USD","LU0326950275.SGD","BK1247","LU0417516902.SGD","BK1521","LU1720050803.USD","LU1688375341.USD","LU0043850808.USD","159892","BK1576","BK0216","LU0708995583.HKD","LU2242644610.SGD","LU0516422366.SGD","LU2328871848.SGD","LU0516422952.EUR","BK1591","BK1515","IE00B0JY6N72.USD","LU1242518857.USD","603259","06618","01801","BK1583","LU1242518931.SGD","LU0039217434.USD"],"gpt_icon":0},{"id":"2532505778","title":"錦欣生殖(01951)出現大手買入84.25萬股，成交價$2.9，涉資244.325萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2532505778","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532505778?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 10:47","pubTimestamp":1746154020,"startTime":"0","endTime":"0","summary":"[大手成交]锦欣生殖(01951)在上午10:47出现大手买入，成交量为84.25万，成交价为港币$2.9，涉资244.325万。至目前为止，股价跌1.375%，今日最高价为$2.93，而最低价为$2.82，总成交量为456.35万股，总成交金额港币$1.31千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2505026282/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1219","BK1597","BK1583","01951"],"gpt_icon":0},{"id":"2532868857","title":"港股異動 | 榮昌生物(09995)再漲超8% 一季度收入同比增近六成 泰它西普gMG數據超出預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2532868857","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532868857?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 10:43","pubTimestamp":1746153814,"startTime":"0","endTime":"0","summary":"消息面上，荣昌生物发布2025年第一季度报告，报告期内公司实现营业收入5.26亿元，同比增长59.17%；实现归母净利润-2.54亿元。中金表示，公司一季度产品收入保持同比亮眼增长，经营现金流改善良好；泰它西普治疗全身型重症肌无力III期临床试验数据优异。该行指出，由于泰它西普gMG数据超出预期，有望打开该适应症的全球市场空间，基于DCF模型，维持公司跑赢行业评级，上调目标价40.6%至45港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU1064131003.USD","09995","BK1574","LU1064130708.USD","LU2148510915.USD","LU1969619763.USD","LU2328871848.SGD","BK0239","BK1161","688331"],"gpt_icon":0},{"id":"2532494852","title":"藥明康德漲4.82% 第一季淨利同比增長89.06% 機構料TIDES業務在今年增長65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532494852","media":"金吾资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532494852?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 10:38","pubTimestamp":1746153522,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药明康德 震荡走强，截至发稿，涨4.82%，报63.05港元，成交额4796万港元。消息面上，药明康德公布2025年第一季度业绩，营业收入约96.55亿元，同比增长20.96%；归属于上市公司股东的净利润约36.72亿元，同比增长89.06%。截至2025年3月末，公司持续经营业务在手订单人民币523.3亿元，同比增长47.1%。高盛发研报指，药明康德今年首季财报强劲，管理层维持其2025财年指引，符合该行预期，认为如果未来1至2个季度持续强势，公司有空间在下半年提高指引。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502103915974d03ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502103915974d03ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2045819591.USD","BK1583","LU2242644610.SGD","02359","LU0052750758.USD","LU0320764599.SGD","LU1046422090.SGD","LU2125910500.SGD","BK1576","BK1141","LU0708995583.HKD"],"gpt_icon":0},{"id":"2532852490","title":"藥明康德盤中異動 股價大漲3.08%報62.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532852490","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532852490?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 10:06","pubTimestamp":1746151583,"startTime":"0","endTime":"0","summary":"2025年05月02日早盘10时06分，药明康德股票出现波动，股价急速拉升3.08%。截至发稿，该股报62.000港元/股，成交量44.5888万股，换手率0.12%，振幅3.99%。药明康德股票所在的生物技术行业中，整体跌幅为1.43%。该信息摘要如下：野村发布研报称，维持药明康德目标价84.59港元以及“买入”评级。2025年第一季度，药明康德收入和盈利增长均重回“两位数”水平;订单积压同比增47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502100623aa2c813c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502100623aa2c813c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2242644610.SGD","LU0320764599.SGD","LU1046422090.SGD","LU2045819591.USD","LU0052750758.USD","LU2125910500.SGD","BK1576","LU0708995583.HKD","BK1141","BK1583","02359"],"gpt_icon":0},{"id":"2532851566","title":"榮昌生物盤中異動 早盤股價大漲5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532851566","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532851566?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 10:03","pubTimestamp":1746151424,"startTime":"0","endTime":"0","summary":"2025年05月02日早盘10时03分，荣昌生物股票出现波动，股价大幅上涨5.26%。荣昌生物股票所在的生物技术行业中，整体跌幅为1.65%。该信息摘要如下：荣昌生物公告，公司已完成2022年A股限制性股票激励计划中A类权益第二个及B类权益首次授予第一个归属期的归属工作，涉及16名A类和100名B类激励对象，共计归属27.6160万股。新增股份于2025年5月8日上市流通，总股本增至54460.824万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502100344aa2c8139&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502100344aa2c8139&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09995","LU1969619763.USD","BK1583","BK1161","LU2328871848.SGD","BK1574"],"gpt_icon":0},{"id":"2532851805","title":"三生製藥盤中異動 早盤快速上漲5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532851805","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532851805?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 10:02","pubTimestamp":1746151322,"startTime":"0","endTime":"0","summary":"2025年05月02日早盘10时02分，三生制药股票出现异动，股价大幅上涨5.02%。截至发稿，该股报12.560港元/股，成交量183.7万股，换手率0.08%，振幅5.35%。三生制药股票所在的药品行业中，整体跌幅为0.05%。其相关个股中，开拓药业-B、三生制药、精优药业涨幅较大，振幅较大的相关个股有华控康泰、开拓药业-B、联康生物科技集团，振幅分别为35.71%、7.50%、6.67%。三生制药公司简介：投资控股,及本集团主要在中国从事开发、生产、营销及销售生物医药产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502100203aa2c8138&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502100203aa2c8138&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","01530","BK1593","BK1161"],"gpt_icon":0},{"id":"2532857014","title":"晶泰控股盤中異動 早盤快速跳水5.04%報4.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532857014","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532857014?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 10:00","pubTimestamp":1746151232,"startTime":"0","endTime":"0","summary":"2025年05月02日早盘10时00分，晶泰控股股票出现异动，股价急速下跌5.04%。截至发稿，该股报4.900港元/股，成交量479.125万股，换手率0.12%，振幅6.20%。资金方面，该股资金流入495.568万港元，流出1687.67万港元。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。晶泰控股股票所在的生物技术行业中，整体跌幅为1.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050210003294ea5a76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050210003294ea5a76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09966","BK1141","BK1161","06998","02228","BK1574","BK1617","BK1583","02105"],"gpt_icon":0},{"id":"2532185122","title":"港股醫藥股走勢疲軟，百濟神州跌近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532185122","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532185122?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 09:55","pubTimestamp":1746150915,"startTime":"0","endTime":"0","summary":"港股医药股走势疲软，百济神州跌近6%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505023395436693.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505023395436693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0588546209.SGD","06160","BK4139","BK1583","ONC","LU0307460666.USD","LU1969619763.USD","BK1161","BK1588","BK1500","LU2328871848.SGD"],"gpt_icon":0},{"id":"2532185132","title":"泰格醫藥盤中異動 股價大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532185132","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532185132?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 09:49","pubTimestamp":1746150576,"startTime":"0","endTime":"0","summary":"2025年05月02日早盘09时49分，泰格医药股票出现异动，股价大幅下挫5.05%。泰格医药股票所在的生物技术行业中，整体跌幅为1.45%。该信息摘要如下：消息面上，4月28日，泰格医药发布公告，于2025年第一季度，该集团取得营业收入15.64亿元，同比减少5.79%;归属于上市公司股东的净利润1.65亿元，同比减少29.61%;基本每股收益0.19元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502094936a6d09c38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502094936a6d09c38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1141","BK1576","BK1583"],"gpt_icon":0},{"id":"2532856663","title":"建業新生活(09983.HK)首席執行官變更","url":"https://stock-news.laohu8.com/highlight/detail?id=2532856663","media":"阿斯达克财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532856663?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 09:25","pubTimestamp":1746149100,"startTime":"0","endTime":"0","summary":"建业新生活(09983.HK) 公布，代纪玲为投入时间处理建业集团相关的其他工作，故辞任执行董事兼首席执行官，自周三(4月30日)起生效。王俊已获董事会委任为首席执行官，自同日起生效。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230822105020622_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230822105020622_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1437454/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09983","BK1258","BK1229","BK1583","BK1542"],"gpt_icon":0},{"id":"2532856996","title":"美團－Ｗ(03690)出現大手賣出75.18萬股，成交價$129.6，涉資9.743千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2532856996","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532856996?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 09:20","pubTimestamp":1746148800,"startTime":"0","endTime":"0","summary":"[大手成交]美团－Ｗ(03690)在上午09:20出现大手卖出，成交量为75.18万，成交价为港币$129.6，涉资9.743千万。至目前为止，股价跌0.537%，今日最高价为$129.6，而最低价为$129.6，总成交量为113.17万股，总成交金额港币$1.471亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT25050236/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["SG9999000459.SGD","LU0880133367.SGD","HMTD.SI","03690","IE00BF5LJ272.USD","LU0499858602.USD","LU0828238088.HKD","LU0143863784.USD","LU1242518931.SGD","LU1224709979.USD","LU1023057109.AUD","LU0463099449.HKD","LU1868837722.USD","SG9999001903.USD","IE00B29SXG58.USD","LU1102505929.USD","LU1880383440.USD","LU2087589342.USD","IE00B0JY6N72.USD","LU0143863198.USD","BK1233","LU0633140727.USD","LU0359201612.USD","LU0211977185.USD","LU0214875030.USD","LU2476274308.USD","MPNGY","LU0456846285.SGD","BK1604","LU0011963245.USD","LU0314109678.HKD","BK1583","LU0054237671.USD","LU0737861699.HKD","LU0873338254.USD","LU1152091754.HKD","LU0132412106.USD","LU1226287529.USD","LU0540923850.HKD","LU1008478684.HKD","LU0054450605.USD","LU0269904917.USD","LU0043850808.USD","LU0633140560.USD","LU0979878070.USD","LU0449509016.USD","LU0708995583.HKD","IE00B3M56506.USD","LU0231483743.USD","LU0594300419.USD"],"gpt_icon":0},{"id":"2532538748","title":"鐵打的高毛利 流水的“醫美茅”：膠原蛋白捧出山西女首富 玻尿酸富豪們身家大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2532538748","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532538748?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 08:39","pubTimestamp":1746146353,"startTime":"0","endTime":"0","summary":"【铁打的高毛利 流水的“医美茅”：胶原蛋白捧出山西女首富 玻尿酸富豪们身家大跌】财富的重新洗牌无疑昭示着医美护肤领域的极速变化，重组胶原蛋白已经开始挑战玻尿酸的地位。谁会笑到最后，仍然考验着各路玩家，而他们的策略将持续影响这场“美丽之战”的格局变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505023395417939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1222","SG9999004311.SGD","09997","BK1100","BK1207","BK1574","LU2488822045.USD","BK1583","02367","09996"],"gpt_icon":0},{"id":"2532535488","title":"翰森製藥(03692.HK)治療卵巢癌藥物獲國家藥監局納入突破性治療藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2532535488","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532535488?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 08:39","pubTimestamp":1746146340,"startTime":"0","endTime":"0","summary":"翰森制药(03692.HK) 公布，旗下B7-H4靶向抗体-药物偶联物注射用HS-20089，获中国国家药品监督管理局批准纳入突破性治疗药物，拟定适应症为用于铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。据介绍，上述药物正于中国开展用于治疗卵巢癌以及其他妇科肿瘤的多项临床研究，其中最高研究阶段为临床III期。(js/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-30 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201021164016783_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201021164016783_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1437436/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03692","BK1583","BK1191","BK1589"],"gpt_icon":0},{"id":"2532589418","title":"開拓藥業(09939.HK)治療雄激素性脫髮藥物臨牀試驗達主要研究終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2532589418","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532589418?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 08:14","pubTimestamp":1746144840,"startTime":"0","endTime":"0","summary":"开拓药业-B(09939.HK) 公布，KX-826与米诺地尔联合治疗中国成年男性雄激素性脱发的Ib/III期临床试验，已达到主要研究终点。公告指，上述临床观察试验是一项开放标签、随机对照研究，旨在评估KX-826联合米诺地尔外用治疗中国成年男性脱发的有效性和安全性，并基于试验结果，优化未来正式III期临床试验方案设计，包括剂量选择、入组患者数量等关键要素.。开拓药业表示，基于该研究成果，公司对已获专利授权的联合疗法治疗潜力更具信心，后续将有序推进III期临床试验。(js/w)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220721143639401_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220721143639401_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1437431/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03347","09939","BK1141","BK1576","BK1574","BK1161","BK1583","BK1515"],"gpt_icon":0},{"id":"2532830168","title":"VESYNC：預期5月7日撤銷股份上市地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2532830168","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532830168?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 08:02","pubTimestamp":1746144120,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　VESYNC（02148）发布公告，公司已根据上市规则第6.15（2）条向联交所申请而联交所已批准撤销股份于联交所的上市地位，于紧接2025年5月7日下午四时正起生效，但须待协议安排生效后方可作实。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-02/doc-inevcpfe8486588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1214","02148","BK1557"],"gpt_icon":0},{"id":"2532699858","title":"VESYNC(02148.HK)私有化獲大法院批准 本月7日起撤銷上市地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2532699858","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532699858?lang=zh_tw&edition=fundamental","pubTime":"2025-05-02 07:59","pubTimestamp":1746143940,"startTime":"0","endTime":"0","summary":"VESYNC(02148.HK) 公布，透过协议安排方式私有化计划已于今年5月1日获大法院批准，至于联交所亦已批准撤销该股份于联交所的上市地位，于今年5月7日下午四时正起生效，惟须待协议安排生效后方可作实。(js/w)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210503162520709_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210503162520709_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1437428/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1214","BK1557","BK1583","02148"],"gpt_icon":0}],"pageSize":20,"totalPage":45,"pageCount":3,"totalSize":895,"code":"91000000","status":"200"}]}}